1. Home
  2. RGEN vs HQY Comparison

RGEN vs HQY Comparison

Compare RGEN & HQY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGEN
  • HQY
  • Stock Information
  • Founded
  • RGEN 1981
  • HQY 2002
  • Country
  • RGEN United States
  • HQY United States
  • Employees
  • RGEN N/A
  • HQY N/A
  • Industry
  • RGEN Medical/Dental Instruments
  • HQY Business Services
  • Sector
  • RGEN Health Care
  • HQY Consumer Discretionary
  • Exchange
  • RGEN Nasdaq
  • HQY Nasdaq
  • Market Cap
  • RGEN 8.0B
  • HQY 8.7B
  • IPO Year
  • RGEN N/A
  • HQY 2014
  • Fundamental
  • Price
  • RGEN $118.07
  • HQY $103.76
  • Analyst Decision
  • RGEN Buy
  • HQY Strong Buy
  • Analyst Count
  • RGEN 12
  • HQY 13
  • Target Price
  • RGEN $172.67
  • HQY $111.77
  • AVG Volume (30 Days)
  • RGEN 822.6K
  • HQY 993.0K
  • Earning Date
  • RGEN 07-29-2025
  • HQY 06-03-2025
  • Dividend Yield
  • RGEN N/A
  • HQY N/A
  • EPS Growth
  • RGEN N/A
  • HQY 70.31
  • EPS
  • RGEN N/A
  • HQY 1.09
  • Revenue
  • RGEN $650,429,000.00
  • HQY $1,199,774,000.00
  • Revenue This Year
  • RGEN $13.93
  • HQY $9.60
  • Revenue Next Year
  • RGEN $14.35
  • HQY $10.04
  • P/E Ratio
  • RGEN N/A
  • HQY $95.19
  • Revenue Growth
  • RGEN 4.88
  • HQY 20.03
  • 52 Week Low
  • RGEN $102.97
  • HQY $65.01
  • 52 Week High
  • RGEN $182.52
  • HQY $115.59
  • Technical
  • Relative Strength Index (RSI)
  • RGEN 39.80
  • HQY 68.51
  • Support Level
  • RGEN $120.55
  • HQY $98.84
  • Resistance Level
  • RGEN $123.71
  • HQY $102.54
  • Average True Range (ATR)
  • RGEN 4.63
  • HQY 2.73
  • MACD
  • RGEN -0.58
  • HQY 0.26
  • Stochastic Oscillator
  • RGEN 7.59
  • HQY 87.26

About RGEN Repligen Corporation

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

About HQY HealthEquity Inc.

HealthEquity Inc provides solutions that allow consumers to make healthcare saving and spending decisions. It provides payment processing services, personalized benefit information, the ability to earn wellness incentives, and investment advice to grow their tax-advantaged healthcare savings. It manages consumers' tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits (CDBs) offered by employers, including flexible spending accounts and health reimbursement arrangements (FSAs and HRAs), and administers Consolidated Omnibus Budget Reconciliation Act (COBRA), commuter and other benefits. It also provides investment advisory services to customers whose account balances exceed a certain threshold. HealthEquity generates its revenue in the United States.

Share on Social Networks: